| Literature DB >> 29977310 |
Jiao Xiao1, Yunfeng Yang2, Yuanrong Zhu3, Yan Qin1, Yifan Li1, Mengjie Fu4, Zhengdong Zhai5, Lingyun Zhu1.
Abstract
OBJECTIVES: Traditional Chinese medicine (TCM) therapy for nonerosive reflux disease (NERD) remains controversial. The aim of this study was to evaluate the efficacy and safety of TCM regimens in NERD treatment.Entities:
Year: 2018 PMID: 29977310 PMCID: PMC5994284 DOI: 10.1155/2018/1505394
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Evaluation criteria on the efficacy of TCM symptoms and syndromes recommended by GCRNDTCM.
| Classification | Detailed description |
|---|---|
| Cure | Clinical symptoms and signs completely disappeared |
| Markedly | Clinical symptoms and signs disappeared or were significantly reduced, with a total score ratio reduction of 2/3 or more |
| Effective | Clinical symptoms and signs were partially reduced, with a total score ratio reduction of 1/3 or more |
| Invalid | Clinical symptoms and signs had no significant change, with total score ratio reduction of 1/3 or less |
TCM, traditional Chinese medicine; GCRNDTCM, Guidelines of Clinical Research of New Drugs of Traditional Chinese Medicine; total score ratio = (pretreatment total score − posttreatment total score)/pretreatment total score ∗ 100%.
Figure 1Flow program of study selection. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097. For more information, visit http://www.prisma-statement.org.
Baseline characteristics of studies included in the meta-analysis.
| Study | Sample size | Sex (M/F) | Age | TCM intervention | Control regimen | Treatment duration | Main outcomes | Randomized method | ||
|---|---|---|---|---|---|---|---|---|---|---|
| T | C | T | C | |||||||
| Cheng et al. 2013 [ | 30/30 | 12/18 | 7/23 | 50.47 ± 11.62 | 46.63 ± 12.40 | Shugan Hewei Decoction, (1 dose/d) | Ome (40 mg/d) | 8 | TER | RNT |
|
| ||||||||||
| Fu and Li 2016 [ | 59/59 | 32/27 | 30/29 | 39.20 ± 10.80 | 41.70 ± 11.60 | Ningshen Qingdan decottion (1 dose/d) | Mos (15 mg/d) and | 8 | TER, RDQs | RNT |
|
| ||||||||||
| Huang et al. 2010 [ | 100/100 | 63/37 | 55/45 | 42.80 ± 11.40 | 38.70 ± 10.80 | Guanyanling Granule (30 g/d) | Ome (40 mg/d) | 4 | TER | RNT |
|
| ||||||||||
| Li 2006 [ | 25/25 | 8/17 | 9/16 | 46.50 ± 13.60 | 45.80 ± 14.20 | Huanglian Wendan Decoction (1 dose/d) | Gas (40 mg/d) and | 4 | TER, RDQs | RNT |
|
| ||||||||||
| Li et al. 2011 [ | 57/55 | 30/27 | 30/25 | 50.91 ± 10.47 | 46.86 ± 14.22 | Tongjiang Granule (30 g/d) | Mos (15 mg/d) | 4 | TER, RDQs | Randomized block |
|
| ||||||||||
| Li et al. 2013 [ | 58/56 | 29/29 | 33/23 | 50.70 ± 10.60 | 47.10 ± 13.30 | Tongjiang Granule (30 g/d) | Ome (40 mg/d) | 4 | TER, RDQs | Sealed envelopes |
|
| ||||||||||
| Pan and Liu 2014 [ | 30/30 | 11/19 | 8/22 | 45.46 ± 13.59 | 46.78 ± 12.48 | Qingdan Hewei decoction (1 dose/d) | Panto (80 mg/d) | 6 | TER | RNT |
|
| ||||||||||
| Wang and Deng 2013 [ | 45/45 | 23/22 | 21/24 | 48.10 ± 6.30 | 47.20 ± 7.40 | SiNi pulvis (1 dose/d) | Eso (40 mg/d) and | 4 | TER, RDQs | RNT |
|
| ||||||||||
| Yang et al. 2013 [ | 64/63 | 21/43 | 17/46 | 50.42 ± 10.01 | 46.27 ± 12.19 | Banxia Xiexin Decoction (1 dose/d) | Panto (40 mg/d) | 8 | TER, RDQs | RNT |
|
| ||||||||||
| Yang and Liu 2014 [ | 50/50 | 27/23 | 28/22 | 22–63 | 22–61 | Jiangni Huatan Yiqi Hewei method (1 dose/d) | Eso (30 mg/d) and | 4 | TER | RNT |
|
| ||||||||||
| Zhang 2009 [ | 30/30 | 17/13 | 15/15 | 38.6 ± 10.6 | 37.70 ± 11.50 | Guanyanling Granule (30 g/d) | Ome (40 mg/d) | 4 | TER, RDQs | RNT |
|
| ||||||||||
| Zhang et al. 2012 [ | 37/36 | 15/22 | 15/21 | 39.23 ± 9.8 | 40.01 ± 7.78 | Jianpi Jiangni Decoction (1 dose/d) | Rabe (20 mg/d) | 4 | TER, RDQs | Sealed envelopes |
|
| ||||||||||
| Zhong et al. 2011 [ | 80/80 | 49/31 | 46/34 | 32.9 ± 18.6 | 34.50 ± 11.30 | Jiangni Hewei Decoction (1 dose/d) | Rabe (20 mg/d) | 8 | TER | RNT |
|
| ||||||||||
| Zhou et al. 2012 [ | 60/60 | 35/25 | 38/22 | 41.8 ± 12.2 | 42.10 ± 11.40 | Shensang Banfo Decoction (1 dose/d) | Rabe (20 mg/d) and | 8 | TER | RNT |
T, TCM group; C, control group; NA, not available; Ome, omeprazole; Mos, mosapride; Eso, esomeprazole; Gas, gaster; Mot, motilium; Panto, pantoprazole; Rabe, rabeprazole; TER, total effect rate; RDQs, Reflux Disease Questionnaire score; RNT, random number tab.
Figure 2Risk of bias graph (a) and risk of bias summary (b).
Figure 3Comparison of a single use of PPIs or Prokinetics (3.1.1) and a combination use of PPIs and Prokinetics (3.1.2) in the total effective rate between two groups.
Figure 4Comparison of the RDQ score after treatment between the TCM and control groups.
Figure 5Comparison of the recurrence rate after stopping treatment for more than 3 months between two groups.
Figure 6Funnel plot of the comparison of TCM versus Western medicine for the outcome of the total effectiveness rate.
Herbal medicines soothing liver in most included studies.
| References | Formula | Herbs soothing liver |
|---|---|---|
| Cheng et al. 2013 [ | Shugan Hewei Decoction | Radix Bupleuri; Fructus Toosendan |
| FuandLi 2016 [ | Ningshen Qingdan decottion | Radix Bupleuri; Cyperus rotundus; Radix Bupleuri; Fructus Toosendan; Curcuma Aromatica |
| Huang et al. 2010 [ | Guanyanling Granule | Pinellia Tuber |
| Li et al. 2011 [ | Tongjiang Granule | Cyperus rotundus; Evodia Rutaecarpa |
| Li et al. 2013 [ | Tongjiang Granule | Cyperus rotundus; Evodia Rutaecarpa |
| Pan and Liu 2014 [ | Qingdan Hewei decoction | Radix Bupleuri; Radix Bupleuri; Fructus Toosendan; Curcuma Aromatica |
| Zhang 2009 [ | Guanyanling Granule | Radix Bupleuri; Fructus Toosendan |
| Zhang et al. 2012 [ | Jianpi Jiangni Decoction | Radix Bupleuri; Radix Paeoniae Alba; Zuo Jin pill |
| Zhong et al. 2011 [ | Jiangni Hewei Decoction | Radix Bupleuri; Radix Bupleuri; Fructus Toosendan |
| Zhou et al. 2012 [ | Shensang Banfo Decoction | Finger Citron |